Dr Asquith first completed a BSc and MSc in Chemistry at the University of Southampton. During this time, he worked for Prof. A. Ganesan on novel asthma targets and epigenetic prostate cancer modulators, which included a 3-month placement abroad at the University of Eastern Finland. He then went on to do a PhD in Medicinal Chemistry at University College London under the supervision of Dr S. Hilton, working on zinc abstractors as a treatment for retroviral infections. This work was part of a broad international Consortium including the University of Zurich, Switzerland and Zelinsky Institute, Moscow, Russia and others, targeting the nucleocapsid protein of FIV/HIV. Subsequently, he continued his interest in innovative ring systems with a short stay at the University of Cyprus working with Prof. P. Koutentis, before joining the Structural Genomics Consortium at the University of North Carolina at Chapel Hill working on chemical probe development for kinases with Prof. T. Willson. This was followed by a move to the School of Medicine to work as the lead medicinal chemist on the Illuminating the Druggable Genome (IDG) kinase program working with Prof. G. Johnson. Starting his own research team, he moved to the University of Eastern Finland to start a medicinal Chemistry program, working on novel kinase indications and understanding kinase solvation shells as a prognostic marker for Kinome wide inhibitor promiscuity.
Research groups
Publications
10/10 items-
Discovery and optimization of narrow spectrum inhibitors of Tousled like kinase 2 (TLK2) using quantitative structure activity relationships
Asquith, Christopher R M; East, Michael P; Laitinen, Tuomo; Alamillo-Ferrer, Carla; Hartikainen, Erkka; Wells, Carrow I; Axtman, Alison D; Drewry, David H; Tizzard, Graham J; Poso, Antti; Willson, Timothy M; Johnson, Gary L. 2024. European journal of medicinal chemistry. 271: -
Enhancing colistin efficacy against Salmonella infections with a quinazoline-based dual therapeutic strategy
Lobertti, Carlos A; Gizzi, Fernán O; Magni, Christian; Rial, Analía; Chabalgoity, José A; Yim, Lucía; Blancato, Víctor S; Asquith, Christopher R M; García Véscovi, Eleonora. 2024. Scientific reports. 14: . 5148 -
Pentathiepins are an understudied molecular prism of biological activities
Pozzetti, Luca; Asquith, Christopher RM. 2024. Archiv der pharmazie. [First published: 09 October 2024]: 1-23 -
The Synthesis and Biological Applications of the 1,2,3-Dithiazole Scaffold
Kalogirou, Andreas S; Oh, Hans J; Asquith, Christopher RM. 2023. Molecules. 28: -
Utilization of Supervised Machine Learning to Understand Kinase Inhibitor Toxophore Profiles
Bieberich, Andrew A; Asquith, Christopher RM. 2023. International journal of molecular sciences. 24: -
Numb-associated kinases are required for SARS-CoV-2 infection and are cellular targets for antiviral strategies
Karim, Marwah; Saul, Sirle; Ghita, Luca; Sahoo, Malaya Kumar; Ye, Chengjin; Bhalla, Nishank; Lo, Chieh-Wen; Jin, Jing; Park, Jun-Gyu; Martinez-Gualda, Belén; East, Michael Patrick; Johnson, Gary L; Pinsky, Benjamin A; Martinez-Sobrido, Luis; Asquith, Christopher RM; Narayanan, Aarthi; De Jonghe, Steven; Einav, Shirit. 2022. Antiviral research. 204: -
Optimization of the 4-anilinoquin(az)oline scaffold as epidermal growth factor receptor (EGFR) inhibitors for chordoma utilizing a toxicology profiling assay platform
Bieberich, Andrew A; Laitinen, Tuomo; Maffuid, Kaitlyn; Fatig, Raymond O; Torrice, Chad D; Morris, David C; Crona, Daniel J; Asquith, Christopher RM. 2022. Scientific reports. 12: . 12820 -
PKN3: a target in cancer metastasis
Temme, Louisa; Laitinen, Tuomo; Asquith, Christopher RM. 2022. Nature reviews drug discovery. 21: -
Small-molecule inhibition of the archetypal UbiB protein COQ8
Murray, Nathan H.; Asquith, Christopher R. M.; Fang, Zixiang; East, Michael P.; Ptak, Naomi; Smith, Robert W.; Vasta, James D.; Zimprich, Chad A.; Corona, Cesear R.; Robers, Matthew B.; Johnson, Gary L.; Bingman, Craig A.; Pagliarini, David J.. 2022. Nature chemical biology. 2023; 19: 230-238 -
Synthesis and evaluation of 1,2,3-dithiazole inhibitors of the nucleocapsid protein of feline immunodeficiency virus (FIV) as a model for HIV infection
Laitinen, Tuomo; Meili, Theres; Koyioni, Maria; Koutentis, Panayiotis A; Poso, Antti; Hofmann-Lehmann, Regina; Asquith, Christopher RM. 2022. Bioorganic and medicinal chemistry. 68: